Halozyme Therapeutics (HALO) Return on Capital Employed Growth (3y) (2014 - 2026)
Halozyme Therapeutics (HALO) Return on Capital Employed Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.89 Bn | 468.10 Bn | 1.35 Bn | 4,893.00 |
| 5 | Vertex Pharmaceuticals | 122.12 Bn | 114.87 Bn | 2.59 Bn | -494.00 |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | -649.00 |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | 4,853.00 |
| 10 | Halozyme Therapeutics | 9.66 Bn | 9.34 Bn | 297.47 Mn | 826.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 826.00 |
| Dec 31, 2025 | 582.00 |
| Sep 30, 2025 | 4,214.00 |
| Jun 30, 2025 | 1,528.00 |
| Mar 31, 2025 | 73.00 |
| Dec 31, 2024 | 141.00 |
| Sep 30, 2024 | -527.00 |
| Jun 30, 2024 | -698.00 |
| Mar 31, 2024 | -686.00 |
| Dec 31, 2023 | -9,061.00 |
| Sep 30, 2023 | 1,098.00 |
| Jun 30, 2023 | 2,494.00 |
| Mar 31, 2023 | 2,979.00 |
| Dec 31, 2022 | 3,321.00 |
| Sep 30, 2022 | 2,702.00 |
| Jun 30, 2022 | 3,170.00 |
| Mar 31, 2022 | 4,385.00 |
| Dec 31, 2021 | 5,051.00 |
| Sep 30, 2021 | 1,224.00 |
| Jun 30, 2021 | 409.00 |